CA-CREDENCE-MEDSYSTEMS
26.1.2021 07:09:06 CET | Business Wire | Press release
Credence MedSystems announced today that Novartis has made a strategic investment in the Company. The investment will advance ongoing development and scaling of Credence’s innovative drug delivery systems, with an initial focus on the Credence Companion® Safety Syringe System. With the investment in Credence, Novartis seeks to support its patients, caregivers, and healthcare professionals by enhancing the safety and user experience during administration of Novartis injectable medications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005138/en/
The Credence Companion allows pharmaceutical manufacturers to provide critical usability and safety features to their end-users. At the completion of the injection, the user receives end-of-dose cues indicating that the full dose has been delivered, and the needle automatically retracts into the syringe barrel. The enhanced usability can contribute to improved adherence, while the passive needle retraction helps protect users from accidental needlesticks and prevents reuse of the syringe.
Credence Companion technology integrates with the syringe before the medication is filled. To facilitate implementation for pharmaceutical manufacturers and offer this technology for a variety of applications and therapeutic fields, a fully integrated solution that is compatible with various syringe barrels is a prerequisite. The integrated approach to safety, where no additional devices need to be assembled after syringe filling, brings operational efficiencies to drug manufacturers. In support of this more efficient approach to the market, a collaboration between Credence and SCHOTT AG for the application of Credence Companion technology with SCHOTT’s pre-fillable glass and polymer syringe systems has recently been announced.
Jeff Tillack and John Merhige, Credence’s COO and CCO, jointly stated, “We are excited to welcome Novartis as a strategic investor. This represents an important validation of Credence technology in the market and helps support our continued growth. We look forward to working together with Novartis to improve the user experience and contribute to better patient outcomes.”
About Credence MedSystems, Inc.
Credence MedSystems is an innovator of drug delivery systems that solve unmet market needs for the pharmaceutical industry. Credence’s philosophy of Innovation Without Change allows pharma manufacturers to impress and protect their end users while preserving their existing processes, sourcing strategies and preferred primary package components. The Companion® family of syringe systems includes proprietary needle retraction technology, syringe reuse prevention and other critical safety and usability features. The Dual Chamber Reconstitution platform offers single-step mixing and injection for medicines that require reconstitution at the time of delivery. The Credence Connect™ brings digital connectivity to any prefilled syringe. Metered dose systems and other novel devices address the needs of specific therapeutic markets such as ocular therapies and cosmetic applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis Increases Revenue Growth Guidance for 202611.6.2026 07:00:00 CEST | Press release
Curatis Holding AG (SIX: CURN) increases its revenue growth guidance for the financial year 2026: the company is forecasting a revenue growth of approximately 40% in 2026, in contrast to the previous outlook of over 25%. Based on preliminary figures for the first five months of 2026, Curatis expects a significantly higher than anticipated revenue growth for 2026. This growth is driven by products that Curatis has marketed for some time, as well as by products added to its portfolio in 2025 and 2026. Under the new guidance, Curatis projects revenues of approximately CHF 15m in 2026, up from CHF 10.8m in 2025. Curatis will publish detailed financial figures for the first six months of 2026 in the half-year report on 21 September 2026. About Curatis Curatis Holding AG is a publicly listed company (CURN.SW) focused on the late stage development and commercialization of drugs for rare diseases and specialty care. Curatis has a sales portfolio of more than 40 products and a pipeline of orpha
Dole Expands Year Two of Highly Successful Global Campaign With Minecraft Designed Towards Maximum Performance With New Pineapple-Focused Experience11.6.2026 07:00:00 CEST | Press release
Nutrition, hydration and energizing recipes among tips for peak gameplay Following the global success of its first healthy gaming collaboration, Dole Food Company today announced the launch of the next phase of its partnership with Minecraft, expanding the campaign with new content, experiences and a fresh focus on pineapple in connection with Dole’s 125-year pineapple heritage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609035908/en/ Dole Food Company has launched a second phase of its popular healthy gaming collaboration with Minecraft with new content, experiences and a focus on pineapples. Launching June 21 and running through October 3, 2026, the campaign builds on Dole’s mission to Make the World a Healthier Place by helping families, gaming enthusiasts and younger audiences around the globe understand how nutritious foods can fuel energy, focus and performance—both on screen and in everyday life. The new campai
Galderma Unveils New Global Survey Data Exploring the Evolving Expectations and Experiences of Patients and Healthcare Professionals With Anti-wrinkle Treatments11.6.2026 07:00:00 CEST | Press release
Results from Galderma’s global survey showed that performance is the top priority for healthcare professionals (HCPs), with long-lasting results, pure, highly active formulations, and fast onset cited as the leading criteria for recommending a treatment1 Reliable clinical outcomes and robust clinical trials were the top two pillars of confidence for HCPs when selecting an anti-wrinkle treatment Ready-to-use liquid formulations are also gaining traction as a key treatment benefit when considering switching to new products1 Patients also rank long-lasting and natural-looking results as the most important benefits when selecting a treatment, and cite increased confidence, improved appearance, and overall well-being as benefits they feel following treatment1 Galderma (SIX: GALD) has released findings from a landmark global survey conducted across the United States (U.S.), Brazil, the United Kingdom (UK), and China – the largest of its kind – exploring the evolving expectations and experien
Abbove strengthens its banking position with the deployment of its platform at ING in Belgium11.6.2026 06:10:00 CEST | Press release
Belgian WealthTech Abbove announces the deployment of its wealth planning platform at ING Belgium. The bank is making a new digital wealth planning experience, ING Financial Compass, available to its Personal Banking and Private Banking clients, built on Abbove technology and specially adapted to its advisory model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610237679/en/ ING Belgium trusts Abbove's technology This collaboration marks a new step in Abbove's development among European financial institutions and reflects how the expectations of banks and their clients are shifting towards a more global approach to wealth guidance. A platform configured for ING Belgium's specific needs While ING Financial Compass is built on Abbove's technological foundation, the solution has been configured to meet the specific needs of ING Belgium, its advisors and its clients. The client journeys, advisory methodologies and wealth obj
Clip Launches Mi Clip, a Digital Wallet Ecosystem, by Partnering with Ant International, Mastercard and Televisa-Univision11.6.2026 06:01:00 CEST | Press release
New open digital wallet ecosystem integrates AI-driven technology, local capabilities, global payment rails, and mass-media reach to provide every Mexican consumer and merchant with digital accounts and credit access Clip, Mexico’s premier financial ecosystem, announced today the launching of Mi Clip, a digital wallet ecosystem designed to accelerate the adoption of digital payments, drive acceptance across merchants and consumers nationwide, and expand access to formal financial services for millions of Mexicans. Mi Clip is supported by commercial and technological solutions from Clip’s payment platform, Ant International’s AI technology, Mastercard’s trusted global payments network and Televisa-Univision’s media outreach. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610247747/en/ Through the initiative, users will be able to access digital wallet accounts that support everyday payments, financial services, and inclusi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom